Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12 | Zendy

Stéphane Billion | Zendy; Bruno Tribout | Zendy; Estelle Cadet | Zendy; Colette Queinnec | Zendy; Jacques Rochette | Zendy; Pascal Wheatley | Zendy; Pierre Bataille | Zendy

Open Access

Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: effect of oral therapy with folic acid and vitamin B12

Author(s) -

Stéphane Billion,

Bruno Tribout,

Estelle Cadet,

Colette Queinnec,

Jacques Rochette,

Pascal Wheatley,

Pierre Bataille

Publication year - 2002

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/17.3.455

Subject(s) - methylenetetrahydrofolate reductase , medicine , vitamin b12 , homocysteine , cyanocobalamin , gastroenterology , vitamin , hematinic , endocrinology , dialysis , biochemistry , genotype , biology , gene

Hyperhomocysteinaemia, a risk factor for atherosclerosis, is common in dialysis patients and particularly in those homozygous for a common polymorphism in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene (C677T transition). B-complex vitamin supplements have been shown to lower plasma total homocysteine (tHcy) concentrations, but the respective effectiveness of folate and oral vitamin B12 is not yet known. Our objectives were: (i) to determine the status of folate and vitamin B12 in a cohort of unsupplemented dialysis patients (ii) to assess the homocysteine-lowering effect of a folate supplement and then of a folate supplement with added vitamin B12. The responses were analysed for the C677T genotypes of MTHFR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research